News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
723,033 Results
Type
Article (41062)
Company Profile (274)
Press Release (681685)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204898)
Career Advice (2029)
Deals (35567)
Drug Delivery (111)
Drug Development (81478)
Employer Resources (173)
FDA (16434)
Job Trends (14969)
News (346783)
Policy (32771)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2572)
Accelerated approval (35)
Adcomms (25)
Allergies (144)
Alliances (49651)
ALS (171)
Alzheimer's disease (1676)
Antibody-drug conjugate (ADC) (318)
Approvals (16699)
Artificial intelligence (522)
Autoimmune disease (159)
Automation (42)
Bankruptcy (361)
Best Places to Work (11647)
BIOSECURE Act (20)
Biosimilars (192)
Biotechnology (181)
Bladder cancer (160)
Brain cancer (58)
Breast cancer (645)
Cancer (4867)
Cardiovascular disease (406)
Career advice (1712)
Career pathing (36)
CAR-T (286)
CDC (46)
Celiac Disease (2)
Cell therapy (755)
Cervical cancer (36)
Clinical research (69695)
Collaboration (1723)
Company closure (4)
Compensation (1172)
Complete response letters (57)
COVID-19 (2720)
CRISPR (93)
C-suite (863)
Cystic fibrosis (143)
Data (6302)
Decentralized trials (2)
Denatured (25)
Depression (135)
Diabetes (504)
Diagnostics (6714)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (255)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (233)
Earnings (90287)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117577)
Executive appointments (981)
FDA (19581)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1484)
Gene editing (199)
Generative AI (44)
Gene therapy (600)
GLP-1 (967)
Government (4670)
Grass and pollen (6)
Guidances (384)
Healthcare (18902)
HIV (62)
Huntington's disease (45)
IgA nephropathy (84)
Immunology and inflammation (256)
Immuno-oncology (60)
Indications (118)
Infectious disease (2996)
Inflammatory bowel disease (196)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (254)
Interviews (317)
IPO (16654)
IRA (50)
Job creations (3656)
Job search strategy (1430)
JPM (57)
Kidney cancer (16)
Labor market (86)
Layoffs (549)
Leadership (32)
Legal (7956)
Liver cancer (92)
Longevity (15)
Lung cancer (657)
Lymphoma (384)
Machine learning (42)
Management (59)
Manufacturing (808)
MASH (164)
Medical device (13787)
Medtech (13843)
Mergers & acquisitions (19987)
Metabolic disorders (1274)
Multiple sclerosis (164)
NASH (16)
Neurodegenerative disease (322)
Neuropsychiatric disorders (89)
Neuroscience (2923)
Neurotech (1)
NextGen: Class of 2026 (6534)
Non-profit (4519)
Now hiring (68)
Obesity (598)
Opinion (263)
Ovarian cancer (168)
Pain (200)
Pancreatic cancer (230)
Parkinson's disease (284)
Partnered (33)
Patents (507)
Patient recruitment (498)
Peanut (57)
People (58998)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21740)
Phase 2 (30674)
Phase 3 (22843)
Pipeline (5442)
Policy (289)
Postmarket research (2565)
Preclinical (9215)
Press Release (64)
Prostate cancer (240)
Psychedelics (48)
Radiopharmaceuticals (283)
Rare diseases (850)
Real estate (5968)
Recruiting (70)
Regulatory (24587)
Reports (53)
Research institute (2394)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (148)
Series A (241)
Series B (192)
Service/supplier (11)
Sickle cell disease (97)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3625)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1013)
Venture capital (89)
Weight loss (381)
Women's health (93)
Worklife (18)
Date
Today (46)
Last 7 days (564)
Last 30 days (2330)
Last 365 days (29860)
2026 (3989)
2025 (30219)
2024 (35253)
2023 (40107)
2022 (51233)
2021 (55766)
2020 (54127)
2019 (46577)
2018 (35048)
2017 (32149)
2016 (31530)
2015 (37600)
2014 (31367)
2013 (26387)
2012 (28595)
2011 (29299)
2010 (27362)
Location
Africa (737)
Alabama (84)
Alaska (7)
Arizona (311)
Arkansas (13)
Asia (39333)
Australia (6439)
California (11405)
Canada (3322)
China (1108)
Colorado (481)
Connecticut (483)
Delaware (342)
Europe (84768)
Florida (1710)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (871)
India (69)
Indiana (527)
Iowa (22)
Japan (437)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1400)
Massachusetts (8161)
Michigan (327)
Minnesota (634)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3025)
New Mexico (28)
New York (3004)
North Carolina (1469)
North Dakota (8)
Northern California (5580)
Ohio (337)
Oklahoma (21)
Oregon (41)
Pennsylvania (2323)
Puerto Rico (24)
Rhode Island (48)
South America (1109)
South Carolina (67)
South Dakota (1)
Southern California (4439)
Tennessee (177)
Texas (1757)
United States (40447)
Utah (340)
Vermont (1)
Virginia (264)
Washington D.C. (81)
Washington State (928)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
723,033 Results for "excision biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
January 27, 2026
·
5 min read
Press Releases
Excision BioTherapeutics Announces Positive Preclinical Data Highlighting the Safety, Potency and Development Progress of the Hepatitis B EBT-107 Program at the ICE-HBV “Hepatitis B Cure Symposium”
September 16, 2025
·
3 min read
Press Releases
Excision BioTherapeutics Announces Publication Highlighting EBT-107 for the Treatment of Chronic Hepatitis B in bioRxiv
May 15, 2025
·
3 min read
Press Releases
Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting
May 14, 2025
·
5 min read
Biotech Bay
Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Excision BioTherapeutics, Inc. today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland.
April 10, 2024
·
3 min read
Press Releases
Sernova Biotherapeutics Announces Warrant Amendments
February 20, 2026
·
3 min read
Biotech Bay
Excision BioTherapeutics Announces Data from the Phase 1/2 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis B
Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure latent viral infectious diseases, summarized the novel presentation of multiple studies at this week’s American Society of Gene and Cell Therapy (ASGCT) meeting.
May 13, 2024
·
4 min read
Biotech Bay
Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024
Excision BioTherapeutics, Inc. today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.
April 16, 2024
·
1 min read
Biotech Bay
Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting
Excision BioTherapeutics, Inc. (“Excision”, the “Company”) today announced that it will present positive data from its herpes simplex virus-1 keratitis program, EBT-104, as well as an overview of a next-generation AAV delivery vector, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.
April 22, 2024
·
8 min read
Press Releases
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
February 19, 2026
·
6 min read
1 of 72,304
Next
